20-F: Oculis Secures Upsized Loan, Advances Key Clinical Programs

Oculis Holding AG reports an upsized loan facility of up to CHF 75 million and significant progress in its clinical pipeline, including expected topline results for OCS-01 and Licaminlimab in 2026.

Summary

• Oculis Holding AG reported a net loss of CHF 99.0 million for the fiscal year ended December 31, 2025, an increase from CHF 85.8 million in 2024.
• Accumulated losses reached CHF 384.5 million as of December 31, 2025.
• Cash, cash equivalents, and short-term financial assets totaled CHF 213.0 million as of December 31, 2025, up from CHF 98.7 million in 2024.
• The company secured an amended and restated loan facility with Kreos Capital VII (UK) Limited (managed by BlackRock, Inc.) for up to the Euro equivalent of CHF 75.0 million, potentially increasing to CHF 100.0 million.
• No amounts were drawn under the amended loan facility during 2025.
• OCS-01, an eye drop for Diabetic Macular Edema (DME), completed enrollment for its two global pivotal Phase 3 clinical trials (DIAMOND-1 and DIAMOND-2) in April 2025, with topline results expected in Q2 2026.
• Licaminlimab (OCS-02), a biologic eye drop for Dry Eye Disease (DED), initiated its registrational Phase 2/3 PREDICT-1 trial in Q4 2025, with topline results anticipated in Q4 2026.
• Privosegtor (OCS-05), a neuroprotective candidate for Optic Neuritis (ON) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), advanced into its PIONEER registrational program in Q4 2025, following positive Phase 2 ACUITY trial results announced in January 2025.
• The PIONEER program includes three pivotal trials: PIONEER-1 and PIONEER-2 for ON (initiated Q4 2025, PIONEER-2 planned H1 2026) and PIONEER-3 for NAION (expected to initiate mid-2026).
• The company completed underwritten offerings in February 2025 and November 2025, raising gross proceeds of $100.0 million (CHF 90.2 million) and $110.0 million (CHF 88.7 million), respectively.
• Research and development expenses increased by 9.6% to CHF 57.1 million in 2025, primarily due to Privosegtor development and OCS-01 clinical trials.
• General and administrative expenses increased by 18.2% to CHF 25.8 million in 2025, mainly due to increased share-based compensation and headcount.
• Fair value adjustment losses on warrant liabilities were CHF 12.3 million in 2025, compared to CHF 15.5 million in 2024, reflecting changes in warrant market prices.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with cautious optimism. While significant capital raises and positive clinical trial advancements for key pipeline candidates are strong positives, the continued and increasing net losses indicate a high burn rate typical of clinical-stage biopharmaceutical companies, necessitating ongoing financial vigilance.

Positives

• Secured an upsized loan facility of up to CHF 75.0 million (potentially CHF 100.0 million) from Kreos Capital VII (UK) Limited, enhancing financial flexibility.
• Successfully completed enrollment for two global pivotal Phase 3 clinical trials (DIAMOND-1 and DIAMOND-2) for OCS-01 in DME, with topline results expected in Q2 2026.
• Announced positive topline results from the Phase 2 ACUITY trial of Privosegtor in ON in January 2025, demonstrating neuroprotective potential and visual function improvements.
• Privosegtor received Breakthrough Therapy designation from the FDA and Orphan Drug designation from both the FDA and EMA for ON.
• Initiated the registrational Phase 2/3 PREDICT-1 trial for Licaminlimab in DED in Q4 2025, utilizing a precision medicine approach with a genetic biomarker.
• Initiated the PIONEER registrational program for Privosegtor in ON and NAION, with three pivotal trials planned for operational synergies and accelerated timelines.
• Successfully raised significant capital through underwritten offerings in February 2025 ($100.0 million gross) and November 2025 ($110.0 million gross), substantially increasing cash reserves.
• Cash, cash equivalents, and short-term financial assets increased to CHF 213.0 million by December 31, 2025, providing funding for at least the next twelve months.

Negatives

• Incurred significant net losses of CHF 99.0 million in 2025, an increase from CHF 85.8 million in 2024, contributing to accumulated losses of CHF 384.5 million.
• Operating expenses increased by 12.2% to CHF 82.9 million in 2025, driven by higher R&D and G&A costs.
• The company has a limited operating history and no products approved for commercial sale, making future success and profitability uncertain.
• Significant reliance on third-party contractors for manufacturing and clinical trials introduces risks of delays, quality issues, and increased costs.
• The manufacturing process for Licaminlimab, a biologic, is highly complex, costly, and requires substantial lead time, with commercial scale not yet tested.
• Fair value adjustment on warrant liabilities resulted in a loss of CHF 12.3 million in 2025.
• Experienced a foreign currency exchange loss of CHF 6.1 million in 2025, primarily due to the weakening of the U.S. dollar against the Swiss Franc.

Risks

• Limited operating history and no products approved for commercial sale make it difficult to evaluate future success and viability.
• Significant and increasing net losses are anticipated for the foreseeable future, requiring additional financing.
• Drug development is a highly uncertain undertaking with a substantial degree of risk, and there is no guarantee of generating revenue or profitability.
• Dependence on the successful development and commercialization of OCS-01, Licaminlimab, and Privosegtor; failure in any could materially harm the business.
• Product candidates may cause undesirable side effects or have unexpected properties, delaying or preventing regulatory approval or limiting commercial profile.
• The manufacture of Licaminlimab, a biologic, is highly complex, costly, and requires substantial lead time, with risks in scaling to commercial production.
• Results of previous clinical trials may not be predictive of future results, and current/planned trials may not satisfy regulatory requirements.
• Interim, topline, and preliminary data from clinical trials may change as more patient data becomes available and are subject to audit and verification.
• Even if approved, product candidates may fail to achieve broad physician and patient adoption due to competition, pricing, or reimbursement issues.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies could make it difficult to sell product candidates profitably.
• Substantial competition from major pharmaceutical and biotechnology companies, academic institutions, and government agencies.
• Complete reliance on third-party contractors for clinical drug supplies, manufacturing, and distribution, including potential sole-source suppliers.
• Rights to develop and commercialize technology are subject to license agreements (e.g., with Novartis and Accure); termination or non-compliance could lead to loss of intellectual property rights.
• Inability to obtain, maintain, protect, and enforce patent or other intellectual property protection could hinder effective competition.
• Regulatory approval processes are highly complex, lengthy, and unpredictable; failure to obtain timely approval would substantially harm the business.
• If OCS-01 does not satisfy Section 505(b)(2) pathway requirements, approval could take longer, cost more, and entail greater risks.
• Economic, financial, geopolitical, epidemiological, or other conditions could result in business disruptions, harming revenue and increasing costs.
• Compromised information technology systems could lead to regulatory actions, litigation, fines, business disruptions, and reputational harm.
• Failure to maintain proper and effective internal controls could impair the ability to produce accurate financial statements on a timely basis.
• Dual-listed public company status incurs significant expenses and management time, potentially negatively impacting financial performance.
• Future issuances of ordinary shares, including under equity incentive plans, would dilute shareholder interest.
• No current intention to pay dividends, so return on investment depends on share price appreciation.
• BCA Public Warrants and BCA Private Warrants may expire worthless, and terms may be amended adversely to holders.
• Redemption of BCA Public Warrants prior to exercise could be disadvantageous to holders, making them worthless.
• Treatment as a passive foreign investment company (PFIC) could subject U.S. investors to adverse U.S. federal income tax consequences.
• Changes to tax laws, treaties, rulings, regulations, or their interpretation could increase effective income tax rates.

Future Outlook

Oculis expects topline results from its OCS-01 DIAMOND-1 and DIAMOND-2 Phase 3 clinical trials for DME in Q2 2026, with a planned NDA submission to the FDA in Q4 2026. Topline results from the Licaminlimab PREDICT-1 registrational trial for DED are anticipated in Q4 2026. The PIONEER registrational program for Privosegtor in ON and NAION is underway, with PIONEER-2 planned for H1 2026 and PIONEER-3 for mid-2026. The company also plans to submit a new IND for Privosegtor for MS in 2026, exploring broader neurological indications.

Management Comments

• We intend to become a global leader in neuro-ophthalmic and ophthalmic therapeutics to realize this mission.
• We plan to focus on successful completion of our key strategic initiatives.
• We believe the use of OCS-01 formulated as a non-invasive, self-administered eye drop, could, if approved, promote a shift in the current treatment paradigm to allow earlier treatment intervention and increase both the treated patient population and the prescribing physician base.
• We believe this precision medicine approach (for Licaminlimab) may allow the candidate to deliver superior outcomes in this patient group, if approved.
• Running the three PIONEER registrational trials concurrently is expected to create operational synergies, improve cost efficiency and accelerate development timelines.

Industry Context

StockSavvy.ai notes Oculis's strategic positioning in high-unmet-need areas within ophthalmology and neuro-ophthalmology, particularly with its non-invasive topical delivery for DME (OCS-01) and precision medicine approach for DED (Licaminlimab). The focus on neuroprotection with Privosegtor addresses a significant gap in treatments for optic neuropathies, a field with limited approved therapies. The industry is highly competitive, with large pharmaceutical and biotech companies like Roche, Novartis, Bayer, Regeneron, Abbvie, and Amgen actively developing or commercializing treatments in these areas. Oculis's reliance on novel mechanisms and biomarker-guided therapy aligns with broader industry trends towards personalized medicine and less invasive treatment modalities, which could provide a competitive edge if successful. However, the market is also characterized by established therapies and the increasing influence of cost-containment measures and generic/biosimilar competition.

Comparison to Industry Standards

• OCS-01 aims to be the first non-invasive topical treatment for DME, differentiating it from currently available invasive treatments like ranimizumab, aflibercept, brolucizumab, faricimab VEGF inhibitors, and dexamethasone/fluocinolone acetonide intravitreal implants (Roche, Novartis, Bayer, Regeneron, Abbvie, ANI Pharmaceuticals).
• Licaminlimab's precision medicine approach for DED, using a genetic biomarker (TNFR1-genotype), is a novel strategy compared to existing FDA-approved therapies like cyclosporine ophthalmic emulsion/solution (Restasis, Cequa, Vevye), lifitegrast ophthalmic solution (Xiidra), loteprednol etabonate ophthalmic suspension (Eysuvis), varenicline solution (Tyrvaya), and perfluorohexyloctane ophthalmic solution (Miebo) from companies like Abbvie, Bausch + Lomb, Alcon, Sun Pharmaceuticals, Harrow, and Viatris.
• Privosegtor is positioned as a first-in-class neuroprotective therapy for ON and NAION, addressing a significant unmet need as there are currently no specific neuroprotective treatments approved by the FDA or EMA for these conditions. Existing competitors in neuro-ophthalmic disorders include Amgen and Domp, but without directly comparable neuroprotective mechanisms for these specific indications.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to or aware of any proceedings that are believed to have a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• The company has a written related person transaction policy for review and approval of transactions involving related persons, as determined by the audit committee.
• Aside from standard employment agreements and a consulting agreement with one director, there are no other transactions between the Company and its directors and executive committee members.
• The remuneration of directors and executive committee members is disclosed in the compensation section.
• Indemnification agreements have been entered into with each director and executive committee member, providing contractual rights to indemnification and expense advancement to the fullest extent permitted by Swiss law.

Stakeholder Impact

• Shareholders: Dilution from recent and future equity issuances, potential for appreciation if product candidates succeed, but also risk of continued losses and warrant expiration.
• Employees: Continued employment and potential for equity-based compensation under the 2023 Plan, but also subject to potential layoffs if growth strategy is not successful.
• Customers (future): Potential for new, non-invasive treatment options for DME, DED, ON, and NAION, addressing unmet medical needs.
• Suppliers/CMOs/CROs: Continued reliance on third-party contractors for R&D and manufacturing, indicating ongoing business for these partners.
• Creditors (Kreos Capital): Secured loan facility provides potential for interest income and fees, with security interests over company assets.

Next Steps

• Expect topline results from OCS-01 DIAMOND-1 and DIAMOND-2 Phase 3 clinical trials in Q2 2026.
• Plan to submit an NDA to the FDA for OCS-01 for the treatment of DME in Q4 2026.
• Anticipate topline results from the Licaminlimab PREDICT-1 registrational Phase 2/3 trial in Q4 2026.
• Continue the PIONEER registrational program for Privosegtor, with PIONEER-2 planned for H1 2026 and PIONEER-3 for mid-2026.
• Plan to submit a new IND for Privosegtor for MS in 2026.
• Loan 1 under the amended facility is available for drawdown until November 15, 2026.
• Loans 2 and 3 are available for drawdown until November 15, 2026, and December 31, 2026, respectively, subject to conditions.

Key Dates

Recommendation

Oculis has demonstrated significant progress in its clinical pipeline, with multiple candidates advancing into registrational trials and positive Phase 2 results for Privosegtor. The company has also successfully raised substantial capital, bolstering its cash position. However, the company continues to incur significant and increasing net losses, which is typical for a clinical-stage biopharmaceutical company but highlights the high burn rate and the long, uncertain path to profitability. The stock is a 'hold' for seasoned investors, balancing the promising pipeline and strong funding with the inherent risks of drug development, regulatory hurdles, and the need for sustained financial performance to achieve commercialization.

Keywords

Ophthalmology, Neuro-ophthalmology, Diabetic Macular Edema, DME, Dry Eye Disease, DED, Optic Neuritis, ON, Non-Arteritic Anterior Ischemic Optic Neuropathy, NAION, Neuroprotection, Clinical Trials, Phase 3, Phase 2/3, Biopharmaceutical, Drug Development, SEC Filing, Loan Facility, Capital Raise, Warrants, Regulatory Approval, Intellectual Property, BlackRock